Liver Diseases Center

INSTITUTE
University Hospitals Digestive Health Institute

MEDICAL DIRECTOR
Pierre M. Gholam, MD
Pierre.Gholam@UHhospitals.org

SURGICAL DIRECTOR

KEY CONTACTS
Anthony Post, MD; S. Martin Cohen, MD

APPOINTMENT LINE
For hospital transfers, please call 216-844-1111.

Coordinators and Contact Information
• For transplant referrals and intake, please call Pamela Diamond at 216-844-3689.
• For medical referrals to the Liver Diseases Center, please call Rhonda Wynn at 216-844-5387.
• For referrals for surgical treatment at the Liver Diseases Center, please call Linda Little at 216-844-0489, option 2.
• For hospital transfers, please call 216-844-1111.

Conditions Treated

  • Chronic hepatitis C infection
  • Non-alcoholic steatohepatitis (NASH)
  • Fatty liver disease
  • End-stage liver disease requiring liver transplantation
  • Cirrhosis of the liver
  • Hepatocellular carcinoma (primary liver cancer)
  • Cholangiocarcinoma (bile duct cancer)
  • Benign liver tumors (hemangioma, adenoma, FNH)

Therapies

  • Liver transplantation
  • Antiviral therapy for HCV infection
  • Surgical resection of malignant and benign liver tumors
  • Radiofrequency ablation for hepatocellular carcinoma
  • Transarterial chemoembolization (TACE) for hepatocellular carcinoma
  • Transarterial radioembolization (TARE/Y90) for hepatocellular carcinoma
  • Systemic chemotherapy for hepatocellular carcinoma

Liver Diseases Center

  • Chronic hepatitis B infection
  • Alcoholic liver disease
  • Primary biliary cholangitis
  • Primary sclerosing cholangitis
  • Hereditary hemochromatosis
  • Vascular liver disease (portal vein thrombosis, Budd-Chiari syndrome)
  • Alpha one antitrypsin deficiency
  • Wilson disease
  • Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma
  • Antiviral therapy for hepatitis B
  • Clinical trials for reversal of liver fibrosis/cirrhosis, fatty liver disease, hepatitis C and liver cancer
  • Treatment of cholestatic liver disease
  • Genetic testing and counseling for inherited disorders of the liver
  • Phlebotomy and follow-up of hereditary hemochromatosis

Distinguishing Features

  • Expedited evaluation of candidacy for liver transplantation for the patients who are most ill
  • Multidisciplinary hepatobiliary tumor board, with broad participation from expert surgeons, hepatologists, medical oncologists, interventional radiologists, pathologists, radiation oncologists and palliative care specialists
  • Nationally and internationally published quality and outcomes data
  • Access to state-of-the-art treatment, including early-phase clinical trials for patients with liver cancer
  • One of the largest hepatitis C treatment clinics in the U.S., with more than 1,000 patients treated and cured in the last two years
  • Access to state-of-the-art clinical trials for all the latest investigational treatments for fatty liver disease
  • Access to first-ever clinical trials for reversal of cirrhosis and liver fibrosis
  • NIH-funded clinical and research program in alcoholic liver disease
Back to Top